SecBot SecBot
Biotech Drug Report Generated Aug 24, 2026

Cabenuva

GSK·GSK plc
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already on the market (approved in US, EU, Japan, China, and other major markets)
Why 4/10
Cabenuva is already approved and commercialized with no pending PDUFA or pivotal readout scheduled in the next ~12 months. The defining binary catalysts (initial FDA approval 2021, every-two-month expansion 2022, adolescent indication expansion) have already passed. At GSK, a diversified large-cap pharma with a $51.65 stock price and broad portfolio, Cabenuva is one of many products and not a concentrated value driver, capping impactScore at 4.
Actionable Insight NEUTRAL

Cabenuva is an established, approved product with no imminent binary catalyst, watch GSK for overall pharma sector trends, HIV market share shifts vs. oral competitors and Gilead's Sunlenca, and ViiV's quarterly sales disclosures rather than a single drug event.

Price Chart

Loading chart...

Executive Summary

Cabenuva (cabotegravir + rilpivirine) is the first and only FDA-approved complete long-acting injectable regimen for HIV-1 treatment, developed by ViiV Healthcare (majority-owned by GSK). Originally approved in January 2021 for monthly dosing, the label was expanded in February 2022 to include every-two-month dosing and later to adolescents aged 12+. For GSK, a diversified global pharma giant (~$51.65/share, 52-week range $38.63-$61.70), Cabenuva is one asset within a broad portfolio and not a binary make-or-break driver. Recent 2026 data (LATITUDE Phase 3 superiority results published in NEJM, AIDS 2026 adolescent data) reinforce the drug's clinical profile but represent label-reinforcing evidence rather than new binary catalysts. The stock carries a "hold" consensus with 14 bullish/15 hold/3 sell analysts and a mean price target of $58.08, implying ~8.4% upside.

How It Works

Cabenuva is a two-drug injectable combination for HIV-1. One component (cabotegravir) blocks the virus from inserting its DNA into human cells. The other (rilpivirine) gums up the virus's reverse transcriptase enzyme, preventing it from copying its genetic material. Given as intramuscular shots every 1 or 2 months (after a short oral lead-in), it replaces the need for daily oral HIV pills.

Trial Status

Cabenuva is already FDA-approved (January 2021 for monthly, February 2022 for every-two-months, and expanded to adolescents). Recent 2026 data: the LATITUDE Phase 3 trial (final data February 2026, published in NEJM) showed Cabenuva was superior to daily oral therapy for maintaining viral suppression in people with adherence challenges. At AIDS 2026 (July 2026), data from the IMPAACT 2017 (MOCHA) study in adolescents showed 94.4% maintained viral suppression at week 96, with >97% preferring injections over daily pills.

The Two-Sided Case

▲ Bull Case4
First-to-market advantage: Cabenuva is the first and only FDA-approved complete long-acting injectable HIV regimen, offering a unique value proposition vs. daily oral pills, with 12 or 6 injection days per year.
Strong recent data: The LATITUDE Phase 3 trial (Feb 2026, NEJM) demonstrated Cabenuva's superiority over daily oral therapy in patients with adherence challenges, a large underserved segment that could expand the addressable market.
Adolescent expansion: Data from AIDS 2026 (July 2026) showed 94.4% viral suppression in adolescents with >97% preferring injections, supporting further label expansion into younger demographics.
GSK's ViiV franchise is the dominant HIV-specialist company globally, giving Cabenuva a strong commercial infrastructure and entrenched prescriber relationships.
▼ Bear Case5
No upcoming binary catalyst: Cabenuva is already approved with no pending PDUFA or pivotal readout, limiting near-term stock-moving potential from this drug specifically.
Competitive pressure: Gilead Sciences' Sunlenca (lenacapavir) is a competing long-acting injectable HIV treatment. Daily oral generics remain a strong entrenched standard of care for most patients.
Commercial adoption headwinds: Long-acting injectables require in-office administration, patient visit compliance, and cold-chain logistics, which can slow uptake vs. convenient daily oral pills.
Minority stake structure: ViiV Healthcare is ~78% owned by GSK (Pfizer and Shionogi hold the rest), so Cabenuva's full revenue contribution is partially attributed to minority partners.
GSK is a large diversified pharma: Cabenuva is one of many products at a $65B+ market-cap company (14 buy/15 hold/3 sell analyst split), limiting single-drug impact on the stock.

Upcoming Catalysts

  • No specific PDUFA or pivotal readout catalyst scheduled for Cabenuva in the next ~12 months; the drug is already approved and commercialized. Watch for quarterly ViiV/GSK sales disclosures, potential additional label expansions (e.g., younger pediatric populations), and competitive dynamics with Gilead's Sunlenca.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GSK plc 6-K GSK ·Originating report

Sources · 10

Hover a chip for the title
1 viivhealthcare.com2 viivhealthcare.com3 businesswire.com4 gsk.com5 accessdata.fda.gov6 fda.gov7 us.gsk.com8 jnj.com9 jnj.com10 cabenuva.com